Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, for use by adults with Type 2 diabetes on glargine U-100 ...

Dexcom has won FDA clearance of the Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy. The clearance ...

Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

Interim CEO Jacob Leach reported "third quarter organic revenue growth of 20% compared to the third quarter of 2024" and highlighted "solid share performance in both our U.S. and international ...

Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group ...

DexCom (NASDAQ:DXCM) reported fourth-quarter 2025 revenue of $1.26 billion, up 13% from $1.11 billion in the prior-year period, as management pointed to strengthening sell-through trends late in the ...

Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...